SG Trading Solutions LLC Purchases Shares of 38,985 Pfizer Inc. $PFE

SG Trading Solutions LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 38,985 shares of the biopharmaceutical company’s stock, valued at approximately $971,000.

Several other institutional investors and hedge funds also recently modified their holdings of PFE. Virtu Financial LLC raised its holdings in shares of Pfizer by 87.5% in the fourth quarter. Virtu Financial LLC now owns 477,207 shares of the biopharmaceutical company’s stock valued at $11,882,000 after purchasing an additional 222,761 shares during the last quarter. Blue Capital Inc. bought a new stake in shares of Pfizer in the fourth quarter worth $216,000. MV Capital Management Inc. acquired a new position in Pfizer during the fourth quarter worth $287,000. Cambient Family Office LLC bought a new position in Pfizer in the fourth quarter valued at $531,000. Finally, White Knight Strategic Wealth Advisors LLC grew its position in Pfizer by 68.5% in the fourth quarter. White Knight Strategic Wealth Advisors LLC now owns 25,036 shares of the biopharmaceutical company’s stock valued at $623,000 after purchasing an additional 10,174 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Negative Sentiment: Pfizer announced that Chief Financial Officer Dave Denton will step down on August 15 for an external opportunity, prompting concerns about leadership continuity and execution at a time when investors are closely watching the company’s 2026 outlook. Reuters article
• Negative Sentiment: The market appears to be treating the CFO transition as a near-term uncertainty, with several reports noting that Pfizer’s shares fell as investors reassessed growth catalysts and financial stability. TipRanks article
• Neutral Sentiment: Pfizer named Cecile Guegan as interim CFO and said it is conducting a comprehensive search for a permanent replacement, which helps reduce uncertainty but does not fully remove investor concerns. Business Wire article
• Neutral Sentiment: The company reaffirmed its full-year 2026 guidance, which should limit downside if management can maintain operational momentum despite the executive transition. TipRanks article
• Positive Sentiment: Recent business updates, including progress on the obesity pipeline and a China partnership expansion, provide longer-term growth optionality, though they were not enough to offset today’s leadership-driven selloff. Yahoo Finance article

Wall Street Analyst Weigh In

PFE has been the topic of several analyst reports. Guggenheim boosted their price target on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Pfizer in a research report on Monday, June 1st. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a report on Monday, March 2nd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $30.00 price target on shares of Pfizer in a research report on Monday, March 9th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $28.82.

Pfizer Stock Down 2.6%

Shares of PFE stock opened at $25.25 on Friday. The firm’s 50-day moving average is $26.26 and its 200-day moving average is $26.33. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The stock has a market cap of $143.94 billion, a price-to-earnings ratio of 19.28 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend was Friday, May 8th. Pfizer’s payout ratio is 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.